Wedbush Has Bearish Estimate for VYGR FY2025 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Wedbush decreased their FY2025 EPS estimates for shares of Voyager Therapeutics in a research note issued on Tuesday, February 11th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($1.12) per share for the year, down from their previous forecast of ($1.03). Wedbush has a "Outperform" rating and a $9.00 price target on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Wedbush also issued estimates for Voyager Therapeutics' Q4 2025 earnings at ($0.29) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($0.94) EPS and FY2028 earnings at ($0.87) EPS.

VYGR has been the topic of several other reports. Cantor Fitzgerald started coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They set an "overweight" rating and a $5.73 target price on the stock. Citigroup started coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a "buy" rating and a $12.00 price objective on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday, January 27th. Finally, StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $15.72.

Voyager Therapeutics Trading Up 1.9 %

VYGR traded up $0.08 during trading hours on Friday, hitting $4.31. 410,197 shares of the company's stock were exchanged, compared to its average volume of 385,764. Voyager Therapeutics has a 12-month low of $4.00 and a 12-month high of $10.66. The firm has a 50 day moving average of $5.53 and a 200 day moving average of $6.20. The firm has a market cap of $235.46 million, a P/E ratio of 6.07 and a beta of 0.91.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 10,778 shares of company stock valued at $58,548 in the last ninety days. Insiders own 4.53% of the company's stock.

Institutional Trading of Voyager Therapeutics

A number of large investors have recently bought and sold shares of VYGR. Cubist Systematic Strategies LLC acquired a new stake in Voyager Therapeutics during the 4th quarter worth $29,000. Tower Research Capital LLC TRC boosted its stake in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management boosted its stake in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after purchasing an additional 2,444 shares during the period. Oxford Asset Management LLP acquired a new stake in Voyager Therapeutics during the 4th quarter worth $60,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock worth $61,000 after purchasing an additional 4,098 shares during the period. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.